Bellecapital International Ltd. grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 7.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 189,204 shares of the biopharmaceutical company's stock after buying an additional 13,364 shares during the quarter. Bellecapital International Ltd.'s holdings in Pfizer were worth $4,794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also made changes to their positions in the company. Mcdonald Partners LLC lifted its position in shares of Pfizer by 9.9% in the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after buying an additional 9,963 shares during the last quarter. Bank of Jackson Hole Trust acquired a new stake in Pfizer in the 4th quarter worth approximately $264,000. Harvey Capital Management Inc. bought a new stake in Pfizer during the fourth quarter worth approximately $544,000. ING Groep NV boosted its position in Pfizer by 48.6% during the fourth quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company's stock worth $26,881,000 after purchasing an additional 331,403 shares during the period. Finally, Strategic Financial Concepts LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $2,281,000. Institutional investors own 68.36% of the company's stock.
Analyst Ratings Changes
Several analysts recently issued reports on PFE shares. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.
Read Our Latest Stock Report on PFE
Pfizer Stock Performance
Shares of NYSE:PFE traded down $0.33 during trading on Friday, hitting $24.51. 39,896,563 shares of the stock were exchanged, compared to its average volume of 41,131,715. The company has a market capitalization of $139.35 billion, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company's fifty day simple moving average is $23.01 and its 200-day simple moving average is $24.97.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.82 earnings per share. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.02%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is 124.64%.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
